Rittmannsberger Hans
Department of Psychiatry, General Hospital Steyr, 4400 Steyr, Austria,
Psychiatr Danub. 2019 Jun;31(2):148-156. doi: 10.24869/psyd.2019.148.
Amisulpride (AMS) in low dosage has been used effectively for treatment of dysthymia. Yet there is a dearth of reports on its use as an augmentation agent in therapy-resistant depression. We deal with this issue presenting case reports and a review of the literature. The addition of 50 mg amisulpride (AMS) to antidepressant therapy in seven patients with depression at different stages of treatment resistance, one of them a case of recurrent brief depression, is described in this report. Augmentation with AMS led to a profound improvement in psychopathology in most patients. The only side effects were elevation of prolactin levels and occasional weight gain. In most cases, improvement occurred early, after only 1-2 weeks of treatment. In some patients, reduction or cessation of AMS led to an immediate and intense recurrence of depressive symptoms that resembled a withdrawal syndrome. Further investigations into the clinical utility and the mode of action of AMS as an augmentation agent are warranted.
低剂量氨磺必利（AMS）已被有效用于治疗心境恶劣障碍。然而，关于其作为难治性抑郁症增效剂使用的报道却很匮乏。我们通过病例报告和文献综述来探讨这一问题。本报告描述了在七名处于不同治疗抵抗阶段的抑郁症患者（其中一名为复发性短暂抑郁症患者）的抗抑郁治疗中添加50毫克氨磺必利（AMS）的情况。使用AMS进行增效治疗使大多数患者的精神病理学症状得到显著改善。唯一的副作用是催乳素水平升高和偶尔的体重增加。在大多数情况下，治疗仅1 - 2周后就出现了早期改善。在一些患者中，减少或停用AMS会导致抑郁症状立即强烈复发，类似于戒断综合征。有必要对AMS作为增效剂的临床效用和作用方式进行进一步研究。
